top of page

Blog
At Drug Science we like to cover different topics relating to drugs. These topics cover the many different ways that psychoactive substances have an impact on our culture and society.


Patterns of recreational substance use, help seeking and harm reduction among UK music festival attendees
Substance use at UK music festivals presents a significant public health challenge, with evolving patterns of drug use, associated risk behaviours, and harm reduction practices among attendees.
Chloe L Rayner, Jason Davies, Ceri A Bradshaw and Alex L Jones
3 days ago2 min read


Drug Science response to Ketamine Harms Assessment
Drug Science responded to the Advisory Council on the Misuse of Drugs’ (ACMD’s) call on Ketamine use, harms and interventions. We hope that our evidence can help to develop rational debate, policy making and scheduling about Ketamine.
Anne Katrin Schlag, David Nutt and Celia Morgan
Aug 194 min read


Germany Pioneers Compassionate Psilocybin Access for Treatment-Resistant Depression in EU First
Germany has recently taken a landmark step by introducing compassionate access to psilocybin for patients with treatment-resistant depression (TRD), marking the first such programme in the European Union.
Jody Chu and James Bunn
Aug 53 min read


UK Government supports ACMD plan to enable research with schedule 1 medicines such as psilocybin and MDMA
Despite the resurgence of research into the clinical efficacy and mechanism of action of psychedelic drugs such as such as psilocybin, LSD, DMT, and MDMA they are currently in Schedule 1 of the Misuse of Drugs regulations 2001.
Jody Chu, James Bunn and Prof Jo Neill
Jul 305 min read


Why do you smoke cannabis? Qualitative interviews of Japanese cannabis users
The number of cannabis-related arrests has been increasing in Japan, accompanied by the implementation of stricter legal penalties. However, there has been little investigation into the motivations behind cannabis use or the reasons for continued use among users in Japan.


Networked narratives: Examining how Purdue Pharmaceuticals shaped public health policy and practice
In 1996, Purdue Pharmaceutical's (Purdue) launched OxyContin, an opioid painkiller, with the largest marketing strategy in pharmaceutical history. Literature has now established that Purdue's marketing of OxyContin was a root cause of the current opioid crisis, responsible for over 600,000 deaths in and beyond North America.


The erosion of safer supply programs in Ontario, Canada: A dangerous step backward
Opioid-related deaths in Ontario remain persistently high, driven largely by an unstable and unregulated drug supply. In response, harm reduction services, such as supervised consumption sites/consumption and treatment services and safer supply programs, have been implemented to reduce the risks of overdose and connect people who use drugs with essential healthcare and social services.


The alcohol hangover product market of the United States of America
A 2019 study revealed more than 80 products available online with implied benefits to alcohol hangover. Since then, several developments may have influenced the market.


Does drug criminalisation increase harmful drug use? A scoping review of underlying mechanisms
This article discusses how unintended side effects from the international regime of drug criminalization may serve to increase harmful drug use among some population segments and performs systematic scoping reviews of two putative underlying dynamics relating to violence victimization and the forbidden fruit or psychological reactance effect.
Petter Grahl Johnstad
Jun 171 min read


Reframing psychedelic regulation: Tools, not treatments
Current regulation frameworks for medicines struggle to address the combination of pharmacological and psychotherapeutic elements in psychedelic therapy.
Max Wolff, Natalie Gukasyan, Leor Roseman and Paul Liknaitzky
Jun 161 min read


Medicinal Cannabis Use Among People with Obsessive Compulsive Disorder: Changes in Quality of Life After Three Months
Obsessive–compulsive disorder (OCD) has an estimated lifetime prevalence between 1 and 2.3% and is associated with considerable worldwide disability, while in the UK, the annual economic costs of this disorder have been estimated to be in excess of GBP 5 billion.


Amanda Feilding
There will never be another like her. As we grieve her loss, we also celebrate her extraordinary life—a life that changed the world in ways we are only beginning to understand.
James Bunn
May 272 min read


Innovating through tradition: kava-talanoa as a culturally aligned medico-behavioral therapeutic approach to amelioration of PTSD symptoms
Kava is a culturally significant Pacific drink used traditionally with cultural practice as a relaxant, to promote dialog in group settings, to aid in sleep and to manage anxiety. Its anxiolytic and sedative properties may link to the presence of kavalactones which are putative low potency GABA ligands.
James Bunn
May 272 min read


A tribute to Hannah Deacon Supermum, Supercampaigner, Super-Beautiful Person.
The whole Drug Science Team is shocked and incredibly saddened by the news of Hannah Deacon’s passing on May 6th, 2025, after ‘a short and brutal illness’
Drug Science
May 132 min read


The role of prejudice and prior contact in support for evidence-based interventions to reduce drug-related deaths: A mixed methods study
Stigmatised attitudes, opinions on opioid use, and prior contact with People Who Use Drugs (PWUD) contribute to what policies are publicly supported and implemented to reduce drug-related deaths. This study examined how these variables relate to policy support for the implementation of supervised injection sites, laws protecting bystanders at the scene of an overdose, and over-the-counter naloxone.
Nicole M Miller, Claire Campbell and Gillian W Shorter
May 42 min read


Probing trends of opioid seizures and drug checking samples under a nascent “decriminalization” framework in Vancouver, Canada
We sought to examine nascent trends surrounding the impacts of police drug seizures in the period after a substantial public policy shift surrounding the personal possession of drugs in British Columbia (BC), Canada. We explored the intersection of drug testing and police opioid seizures in Vancouver, BC.
Tyson Singh Kelsall, Dustin Godfrey and Jenn McDermid
May 31 min read


Clarifying the legal landscape of psilocybin regulation: A medico-legal perspective
The global regulatory landscape for psilocybin and PSILO-AT remains highly variable, with significant differences in the scope and clarity of medical governance.
Octavian Brinzei
Apr 275 min read


Minorities’ diminished psychedelic returns: Depression, suicide, distress, and serious mental illness
Although there is growing support for the protective effects of psychedelics on mental health, recent evidence finds racial and ethnic minorities gain fewer benefits.
Sean M Vina
Apr 211 min read


Poppy seed addiction: A brewing crisis? A novel case series examining patterns, perceptions and potential risks associated with excessive poppy seed use
The increasing incidence of opioid dependence linked to the consumption of unwashed poppy seeds (UPSs) is an emerging public health concern.


Dose-response relationship between blood concentrations of THC and crash culpability risk: An updated meta-regression of culpability studies
A recent meta-analysis in Drug Science, Policy and Law on the risk associated with the detection of tetrahydrocannabinol (THC) in blood and
Matthew A Albrecht Razi Hasan Damir Kekez and Huaqiong Zhou
Mar 271 min read


Irresponsible publicity related to an unpublished vaping study
On the 26th of February 2025, Clive Bates wrote to an academic at Manchester Metropolitan University, Dr Maxime Boidin, about generating irr
Clive Bates
Feb 266 min read
bottom of page